Desmopresin
PreclinicalSmall molecule
Desmopresin is one of 18 small molecule programs targeting Enuresis. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
26 competitors in Enuresis
#DrugCompanyPhaseTrials
1Indocin
LLife Extension Foundation Inc.
Approved
Pitressin
AAultman Health Foundation
Approved
Advil
KKenvue Brands
Approved
Myrbetriq
AstellasPhase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Oxytrol
WWim Janssens
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 2
Strattera
MMap77
Phase 1
Minirin
FerringPhase 3
Depacon
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Desmopresin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RRabin Medical Center